Janux

Janux Therapeutics is developing unique immunotherapies that generate tumor-specific immune responses to attack and kill tumors without damaging the patient's healthy tissue. Additionally, Janux’s technology can be applied to immunotherapies targeting all three phases of the anti-tumor immune response. It is believed that combining Janux’s tumor-specific activation with multi-phase anti-tumor signaling will significantly enhance safety, broaden the therapeutic dosing range, and maximize patient response.